Recent studies have highlighted promising avenues for future exploration; early-phase data have demonstrated the efficacy of selumetinib, an MEK inhibitor, in reducing the size of inoperable plexiform neurofibromas in children with NF1. This evidence concerns the gene MAP2K7 and neurofibromatosis type 1.